Pharmaceutical | Tokio X'press - Part 99

💊Kyowa Hakko Kirin News、Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application 20171010

Wednesday October 11th, 2017By Tokio X'press FDA, JPN kyowa-kirin

💊Notice Regarding Implementation of New Drug Discovery Program “JOINUS” Using Drug Repositioning Compound Libraries by Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi Sankyo

Wednesday October 11th, 2017By Tokio X'press JPN, Pharmaceutical Astellas

💊Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197 (Tivantinib)

Friday October 6th, 2017By Tokio X'press JPN, Pharmaceutical kyowa-kirin

💡ChromaJean to Launch at Takeda’s Shonan Research Center 2017年10月2日

💡ChromaJean to Launch

Monday October 2nd, 2017By Tokio X'press JPN, Pharmaceutical ChromaJean Inc

💡ChromaJean to Launch

💊Bristol-Myers Squibb Company, Opivo® (generic name: niborumab), approved as Fda as a treatment for hepatocellular cancer patients with treatment history with sorafenib 20170927

💊Bristol-Myers Squibb

Friday September 29th, 2017By Tokio X'press FDA, JPN ONO

💊Bristol-Myers Squibb